101 related articles for article (PubMed ID: 18176306)
1. Shorter treatment for hepatitis C genotype 4 may be a possibility.
Iqbal S; Mansour M; Cerulli MA
South Med J; 2008 Jan; 101(1):106. PubMed ID: 18176306
[No Abstract] [Full Text] [Related]
2. Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?
Liang TJ
N Engl J Med; 2007 Jul; 357(2):176-8. PubMed ID: 17625131
[No Abstract] [Full Text] [Related]
3. A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.
Huang CF; Dai CY; Huang JF; Chuang WL; Yu ML
Hepatology; 2009 Apr; 49(4):1395-6; author reply 1396. PubMed ID: 19330867
[No Abstract] [Full Text] [Related]
4. Treatment duration for genotypes 2 and 3: still confusing after all these years.
Jensen DM
J Clin Gastroenterol; 2010 Sep; 44(8):527-8. PubMed ID: 20628314
[No Abstract] [Full Text] [Related]
5. [High dosage induction brings new hope].
MMW Fortschr Med; 2005 Dec; 147(51-52):68. PubMed ID: 16404784
[No Abstract] [Full Text] [Related]
6. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
Buti M; Valdés A; Sánchez-Avila F; Esteban R; Lurie Y
Hepatology; 2003 May; 37(5):1226-7. PubMed ID: 12717407
[No Abstract] [Full Text] [Related]
7. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
Henry MJ
N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16167381
[No Abstract] [Full Text] [Related]
8. Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses.
Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
Hepatology; 2010 May; 51(5):1861-2; author reply 1862-4. PubMed ID: 20432270
[No Abstract] [Full Text] [Related]
9. [Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
Klinker H
MMW Fortschr Med; 2003 Oct; 145(41):39-40. PubMed ID: 14655480
[No Abstract] [Full Text] [Related]
10. [Guidelines for treatment of hepatitis C].
Iino S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):342-6. PubMed ID: 15359818
[No Abstract] [Full Text] [Related]
11. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
Borg BB; Hoofnagle JH
N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16162894
[No Abstract] [Full Text] [Related]
12. [Therapeutic strategies for hepatitis C].
Tsubota A; Kumada H
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):441-7. PubMed ID: 15359839
[No Abstract] [Full Text] [Related]
13. Current management of hepatitis C in New Zealand.
Gane E
N Z Med J; 2001 Mar; 114(1128):101-2. PubMed ID: 11346152
[No Abstract] [Full Text] [Related]
14. Delaying HCV treatment in HIV-positive patients.
Carter M
IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
[No Abstract] [Full Text] [Related]
15. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Andriulli A; Mangia A
N Engl J Med; 2007 Oct; 357(16):1660; author reply 1661-2. PubMed ID: 17942881
[No Abstract] [Full Text] [Related]
16. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
Asahina Y; Izumi N
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
[No Abstract] [Full Text] [Related]
17. [Hepatitis C: 15 years of life].
Perez V
Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S9-10. PubMed ID: 20214283
[No Abstract] [Full Text] [Related]
18. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Liu CH; Chen DS; Kao JH
N Engl J Med; 2007 Oct; 357(16):1661; author reply 1661-2. PubMed ID: 17948345
[No Abstract] [Full Text] [Related]
19. Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there?
Tillmann HL
J Hepatol; 2013 Mar; 58(3):412-4. PubMed ID: 23247067
[No Abstract] [Full Text] [Related]
20. Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon alpha-2b and ribavirin.
Sherker AH; Senosier M; Kermack D
Hepatology; 2003 Jan; 37(1):223. PubMed ID: 12500209
[No Abstract] [Full Text] [Related]
[Next] [New Search]
